Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
92 hedge funds and large institutions have $34M invested in Lumos Pharma, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 26 reducing their positions, and 24 closing their positions.
13% less funds holding
Funds holding: 106 → 92 (-14)
14% less call options, than puts
Call options by funds: $234K | Put options by funds: $271K
15% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 26
54% less capital invested
Capital invested by funds: $74.4M → $34M (-$40.4M)
58% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$3.15M |
| 2 |
JP Morgan Chase
New York
|
+$2.34M |
| 3 |
Two Sigma Investments
New York
|
+$1.23M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$800K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$786K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$7.67M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.62M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$2.42M |
| 4 |
First Eagle Investment Management
New York
|
-$2.36M |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$896K |
LUMO Hedge Fund Activity: Q3 2018 in Review
92 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q3 2018, worth a combined $34M — down 54% from $74.4M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of LUMO and 10 opened new positions — a net loss of 14 holders — while 26 trimmed existing stakes and 22 added.
The largest buyer was Renaissance Technologies, adding an estimated $3.15M. The largest seller was Redmile Group, exiting entirely with an estimated $7.67M sold.
- 92 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q3 2018, down from 106 in Q2 2018.
- Funds reported $34M of Lumos Pharma, Inc. Common Stock stock for Q3 2018, down 54% quarter-over-quarter.
- 10 funds opened new Lumos Pharma, Inc. Common Stock positions in Q3 2018 and 24 closed out, a net change of -14 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q3 2018 was Renaissance Technologies, an estimated $3.15M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q3 2018 was Redmile Group, an estimated $7.67M sold.
Based on aggregated 13F filings for Q3 2018.